Form 4: DURECT Corp Acquired by Bausch Health for $1.75/Share Plus CVR

DURECT Corporation has been acquired by Bausch Health Americas, Inc. through a tender offer and subsequent merger, with shareholders receiving $1.75 per share cash and a contingent value right.

Summary

• DURECT Corporation was acquired by Bausch Health Americas, Inc. (Parent) through its subsidiary BHC Lyon Merger Sub, Inc. (Purchaser).
• The acquisition was completed via a tender offer followed by a merger, effective September 11, 2025.
• Shareholders tendering their common stock received $1.75 per share in cash, plus one non-tradeable contingent value right (CVR).
• The CVR entitles holders to a pro rata portion of two milestone payments, totaling up to $350,000,000, contingent on achievement of specified milestones.
• DURECT Corporation now operates as a wholly-owned subsidiary of Bausch Health Americas, Inc.
• Stock options with an exercise price less than $1.75 were accelerated and treated like common stock in the merger.
• Stock options with an exercise price equal to or greater than $1.75 were canceled, with former holders eligible for a cash retention bonus tied to net sales milestones.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the merger successfully closed, providing shareholders with immediate cash and potential future upside via CVRs. However, the CVRs are non-tradeable and milestone-dependent, introducing some uncertainty. For option holders, some options were canceled, but a retention plan is in place.

Positives

• Shareholders received a cash payment of $1.75 per share, providing immediate liquidity.
• Shareholders also received a contingent value right (CVR), offering potential future upside of up to $350,000,000 based on milestone achievements.
• Certain stock options were accelerated, allowing holders to participate in the tender offer.
• Holders of canceled stock options are eligible for a cash retention bonus, providing an incentive for continued performance under the new ownership.

Negatives

• DURECT Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Stock options with exercise prices equal to or greater than $1.75 were canceled, meaning these options lost their direct equity value.
• The CVRs are non-tradeable, limiting liquidity for the contingent value.
• The CVR payments are subject to the achievement of specific milestones, introducing uncertainty regarding their realization.

Risks

• Milestone Achievement Risk: The contingent value rights (CVRs) are dependent on the achievement of specified milestones, which may not be met, potentially resulting in no additional payments to CVR holders.
• Retention Plan Risk: The cash retention bonuses for former option holders are subject to the achievement of certain net sales milestones, meaning these bonuses are not guaranteed.

Future Outlook

DURECT Corporation will continue as a wholly-owned subsidiary of Bausch Health Americas, Inc. Future payments to CVR holders and retention bonuses for former option holders are contingent on the achievement of specified milestones, including net sales milestones.

Management Comments

• Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes, plus one non-tradeable contingent value right per share.
• At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger.
• Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors.

Industry Context

This acquisition represents a consolidation within the pharmaceutical or biotechnology sector, where larger companies often acquire smaller firms to gain access to pipeline assets, technology, or market share. The use of CVRs is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this acquisition is a common practice in the biotechnology and pharmaceutical industry, particularly for deals involving companies with pipeline assets or products awaiting regulatory approval or commercialization. Similar structures have been used in acquisitions like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of MyoKardia.
• The cash component of $1.75 per share provides immediate value, while the CVR offers potential upside, aligning with typical M&A strategies that balance immediate returns with future growth potential.
• The cancellation of out-of-the-money options (exercise price >= cash amount) and the provision of a retention plan for key personnel is standard practice to ensure continuity and incentivize performance post-acquisition.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $1.75 per share in cash and a non-tradeable contingent value right (CVR) for potential future payments, but lost direct equity ownership in a public company.
• Employees (Option Holders): Those with in-the-money options saw acceleration and participation in the tender offer; those with out-of-the-money options had them canceled but are eligible for a cash retention bonus tied to performance milestones.
• Company (DURECT Corp): Became a wholly-owned subsidiary, gaining the backing and resources of Bausch Health Americas, Inc., but losing its independent public status.
• Parent Company (Bausch Health Americas, Inc.): Successfully acquired DURECT, potentially expanding its product portfolio or pipeline.

Next Steps

• Achievement of specified milestones for CVR payments.
• Achievement of net sales milestones for cash retention bonuses to former option holders.
• Integration of DURECT Corporation as a wholly-owned subsidiary into Bausch Health Americas, Inc.

Key Dates

Recommendation

The company has been acquired and is no longer publicly traded. Existing shareholders would have already tendered their shares or had them converted into the merger consideration ($1.75 cash plus CVR). There is no public stock to buy or hold.

Keywords

DURECT Corporation, DRRX, Bausch Health Americas, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Corporate Governance, SEC Form 4